A Prospective, Randomized Clinical Study of Two Phakic Toric Implantable Lenses

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

172 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-10

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective: To compare the efficacy and the residual refractive error of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patient with co-existing astigmatism. Secondary Objectives: To evaluate and compare the safety of EYECRYLTM Phakic toric versus Visian® Toric ICL in moderate to high myopic patients with co-existing astigmatism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Toric IOL vs Non-toric IOL With LRI for Corneal Astigmatism

NCT03633851

Corneal Astigmatism

UNKNOWN NA

Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses

NCT01268540

Aphakia Cataract

COMPLETED NA

A Planned Study at Multiple Sites is Being Done to Compare the Results of Two Types of Trifocal Toric Intraocular Lenses Used in Cataract Surgery

NCT07232615

Presbyopia Correction Astigmatism Cataract

RECRUITING NA

Comparison of Clinical Outcomes of Toric Intraocular Lens

NCT03085901

Astigmatism

COMPLETED NA

Assessing the Astigmatism Reducing Effect With Toric IOLs in Eyeswith Low Astigmatism

NCT03538964

Cataract Astigmatism

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.1

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia, Moderate Myopic Astigmatism Myopia, Degenerative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EYECRYLTM Phakic Toric Intraocular Lens Treatment Arm

Patients will be implanted with Eyecryl Phakic Toric IOL based on randomization.

Group Type EXPERIMENTAL

EYECRYLTM Phakic Toric Intraocular Lens Treatment Arm

Intervention Type DEVICE

The patients will be implanted with Eyecryl Phakic IOL at this arm based on randomization.Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.

Visian® Toric ICL Treatment Arm

Patients will be implanted with Visian® Toric ICL based on randomization.

Group Type ACTIVE_COMPARATOR

Visian® Toric ICL Treatment Arm

Intervention Type DEVICE

The patients will be implanted with Visian® Toric Implantable Contact Lens at this arm based on randomization. Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EYECRYLTM Phakic Toric Intraocular Lens Treatment Arm

The patients will be implanted with Eyecryl Phakic IOL at this arm based on randomization.Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.

Intervention Type DEVICE

Visian® Toric ICL Treatment Arm

The patients will be implanted with Visian® Toric Implantable Contact Lens at this arm based on randomization. Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 21 years old or older.
* Calculated IOL Power is within the range of the investigational IOLs
* Corneal Cylindrical error within the range defined in the clinical investigation plan
* Subject has monocular UCVA 0.5 LogMAR or worse
* Subject has had a stable refraction (±0.5D; ±1.0D for higher refractive errors), as expressed by manifest refraction spherical equivalent (MRSE) for a minimum 12 months prior to surgery, verified by consecutive refractions and/or medical records or prescription history.
* Subject, who is a current contact lens wearer, needs to demonstrate a stable refraction (±0.5D) expressed as MRSE, on two consecutive examination dates and stability of the refraction is determined by the following criteria:

1. Contact lenses were not worn for at least 2 weeks or 3 days prior to the first refraction.
2. Two refractions were performed at least 7 days apart.
* Subject, who is expected to have residual postoperative cylindrical refractive error of ≥1D, has been given the opportunity to experience his/her best spectacle vision with the anticipated correction.
* Expected dilated pupil size at least large enough to visualize the axis marking.
* Patients willing to attend all follow-up appointments
* Patients must sign and be given a copy of the written Informed Consent form

Exclusion Criteria

* Subject with acute and chronic disease or illness that would increase the operative risk or confound the outcomes of the evaluation.
* Subject taking systematic medication that can confound the outcome of the study or increase the risk to the subject
* Subject with ocular condition that may predispose the subject to future complications
* Subject with previous intraocular or corneal surgery
* Subject with less than the minimum endothelial cell density 2000 cells/mm² at the time of enrollment
* Pregnant or planning to become pregnant, or is lactating during the course of the evaluation
* Other condition associated with fluctuation of hormones
* ACD measured from the endothelium lower than 2.8 mm
* Concurrent participation in another drug or device evaluation.
* Any cataract of any grade.
* Coefficient of variation of endothelial cell area \>0.45
* Percent Hexagonality of endothelial cell shape ≤ 45%
* Monocular subject
* Vulnerable subjects as defined in section 12.3.10

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No